Quick Answer
CNS Pharmaceuticals, Inc. reported Cash and Equivalents of $7.20 million for fiscal year 2025.
CNS Pharmaceuticals, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $7.20M | +11.4% |
| 2024 | $6.46M | +1077.5% |
| 2023 | $548.7K | -94.5% |
| 2022 | $10.06M | +100.9% |
| 2021 | $5.00M | -64.4% |
| 2020 | $14.04M | +93.9% |
| 2019 | $7.24M | +2461.1% |
| 2018 | $282.7K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $9.86M | +41.5% | -18.7% |
| June 30, 2025 | $12.13M | +713.2% | -7.0% |
| March 31, 2025 | $13.05M | +1500.5% | +101.9% |
| December 31, 2024 | $6.46M | +1077.5% | -7.3% |
| September 30, 2024 | $6.97M | +666.7% | +367.5% |
| June 30, 2024 | $1.49M | -65.1% | +83.0% |
| March 31, 2024 | $815.2K | -84.0% | +48.6% |
| December 31, 2023 | $548.7K | -94.5% | -39.7% |
- CNS Pharmaceuticals, Inc. showed an increase of +11.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2018–2025 period, CNS Pharmaceuticals, Inc.’s cash and equivalents has grown by 2446.9% (from $282.7 thousand to $7.20 million).
- The most recent figure is from CNS Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: